SCHEMBL992344

SCHEMBL992344

CCCCCCCCCCCCCCOc1ccc(C(=O)OCC(=O)N2CCN(C3CCCCC3)CC2)o1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.47
▸ TDP1 Q9NUW8 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ ALDH1A1 P00352 4/20 0.45
▸ TSHR P16473 1/20 0.45
▸ THRB P10828 1/20 0.45
▸ KDM4E B2RXH2 3/20 0.44
▸ CASP6 P55212 2/20 0.43
▸ POLB P06746 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ MAPK1 P28482 1/20 0.40
▸ PDE3B Q13370 1/20 0.39
▸ PDE3A Q14432 1/20 0.39
▸ GAA P10253 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ SCN5A Q14524 1/20 0.38
▸ SCN2A Q99250 1/20 0.38
▸ SCN10A Q9Y5Y9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL991535 0.88 TDP1 (0.55) KMT2ATDP1MEN1CASP6POLB
SCHEMBL12950492 0.84 THRB (0.44) KMT2ATDP1ALDH1A1TSHRTHRB
SCHEMBL992135 0.83 POLB (0.61) KMT2ATDP1MEN1ALDH1A1KDM4E
SCHEMBL1079065 0.81 ALDH1A1 (0.57) KMT2ATDP1MEN1ALDH1A1TSHR
SCHEMBL11980693 0.81 TDP1 (0.57) KMT2ATDP1ALDH1A1TSHRTHRB
SCHEMBL19442012 0.80 KDM4E (0.50) KMT2ATDP1ALDH1A1TSHRTHRB
SCHEMBL991053 0.78 KMT2A (0.51) KMT2ATDP1MEN1ALDH1A1
SCHEMBL992517 0.77 LMNA (0.54) KMT2ATDP1MEN1ALDH1A1TSHR
SCHEMBL991587 0.76 ALDH1A1 (0.52) KMT2ATDP1MEN1ALDH1A1TSHR
SCHEMBL14857328 0.75 KDM4E (0.41) KMT2AALDH1A1TSHRTHRBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9782382-B2 TOFA analogs useful in treating dermatological disorders or conditions DERMIRA (CANADA), INC. (US) 2017-10-10 — — US claimed
US-20160338988-A1 TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS DERMIRA (CANADA) INC (US) 2016-11-24 — — US claimed
EP-2641906-B1 Tofa analogs useful in treating dermatological disorders or conditions DERMIRA CANADA INC (US) 2015-04-22 — — EP claimed
US-8884034-B2 TOFA analogs useful in treating dermatological disorders or conditions DERMIRA (CANADA), INC. (US) 2014-11-11 — — US claimed
EP-2641906-A1 Tofa analogs useful in treating dermatological disorders or conditions Dermira (Canada), Inc. (US) 2013-09-25 — — EP claimed
EP-2451796-B1 TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS DERMIRA CANADA INC (US) 2013-04-17 — — EP claimed
US-20120208807-A1 TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS Valocor Therapeutics, Inc. (CA) 2012-08-16 — — US claimed
EP-2451796-A1 TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS Dermira (Canada), Inc. (CA) 2012-05-16 — — EP claimed
WO-2011005660-A1 TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS Valocor Therapeutics, Inc. (CA) 2011-01-13 — — WO claimed
US-20260034091-A1 Compositions and Methods for Treating Metabolic Disorders UNIV CALIFORNIA (US) 2026-02-05 — — US disclosed
EP-4561557-A1 COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS The Regents of the University of California (US) 2025-06-04 — — EP disclosed
WO-2024026012-A1 COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-02-01 — — WO disclosed
US-9782382-B2 TOFA analogs useful in treating dermatological disorders or conditions DERMIRA (CANADA), INC. (US) 2017-10-10 — — US disclosed
US-20160338988-A1 TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS DERMIRA (CANADA) INC (US) 2016-11-24 — — US disclosed
US-8884034-B2 TOFA analogs useful in treating dermatological disorders or conditions DERMIRA (CANADA), INC. (US) 2014-11-11 — — US disclosed
EP-2641906-A1 Tofa analogs useful in treating dermatological disorders or conditions Dermira (Canada), Inc. (US) 2013-09-25 — — EP disclosed
EP-2451796-B1 TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS DERMIRA CANADA INC (US) 2013-04-17 — — EP disclosed
US-20120208807-A1 TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS Valocor Therapeutics, Inc. (CA) 2012-08-16 — — US disclosed
EP-2451796-A1 TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS Dermira (Canada), Inc. (CA) 2012-05-16 — — EP disclosed
WO-2011005660-A1 TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS Valocor Therapeutics, Inc. (CA) 2011-01-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160338988-A1 TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS FAH, CUTA, ALOX5AP KMT2A 2716/4885TDP1 3363/4885MEN1 4056/4885
US-20120208807-A1 TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS FAH, CUTA, ALOX5AP KMT2A 3026/4885TDP1 3323/4885MEN1 3929/4885
US-20260034091-A1 Compositions and Methods for Treating Metabolic Disorders LIPC, GPR119, PNLIP KMT2A 3144/4885TDP1 4755/4885MEN1 3713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback